M.Sc. Econ. Born 1980. Active in the company since 2020. She is the CEO of Moberg Pharma and has more than 15 years of experience in the pharmaceutical industry as well as CFO of other biotech companies as Athera Biotechnologies AB
and Lipopetide AB and as independent technology licensing consultant. Board member of Saniona AB.
Shareholding: 34 160 shares. Independent in relation to the company and the owners.
Born 1953. Active in the company since 2020. MD, DMSc. Torben has a medical degree and a bachelor's degree in philosophy from the University of Copenhagen and specializes in anesthesia and pain treatment and one of the inventors of BupiZenge. Represents Oracain APS II. Chair of the Danish Lung patient society and the Committee for Medical Product Surveillance at Danish Medical Agency. Board member at Augusta Victoria Hospital, Jerusalem and professor at Lanzhou University, China. His former experience includes Medical director at Hvidovre Hospital, University of Copenhagen, board member of European Society of Regional Anesthesia and several other scientific boards.
Shareholding: 22 834 shares. Independent in relation to the company and the owners.
M.Sc. Econ. Born 1967. Active in the company since 2020. Represents Östersjöstiftelsen and has extensive experiences from leadership roles within the finance and technology sector, e.g.as CEO at Morphic Technologies AB, CFO at Hexaformer and senior corporate finance associate at ABG Sundal Collier and auditor at Arthur Andersen. He is Chairman of the board at Dilafor ad a board member at Oatly, Phoniro and Axelar as well as chairman of the nomination committee of Lightlab, Pharmanest and Cellimpact.
Shareholding: 1 500 shares. Independent in relation to the company and the owners.
M.Sc. Born 1958. Active in the company since 2020. Represents Linc and has extensive experiences from leadership roles within pharma and biotech, e.g.as Business Unit Director and General Manager at Baxter AB and Pharmalink AB. General Manager and Senior Vice President at Genzyme/Sanofi Genzyme responsible for Rare Diseases in Europe/EMEA. Board member off Calliditas, PCI Biotech and Bio-me. Industrial advisor to Investinor.
Shareholding: 14 635 shares. Independent in relation to the company and the owners.